https://rxinsider.ai/daily1.0 https://rxinsider.ai/deal-tracker/daily0.9 https://rxinsider.ai/deals/daily0.8 https://rxinsider.ai/negotiations/daily0.8 https://rxinsider.ai/policy/daily0.8 https://rxinsider.ai/pipeline/daily0.8 https://rxinsider.ai/money/daily0.8 https://rxinsider.ai/people/daily0.8 https://rxinsider.ai/data/daily0.8 https://rxinsider.ai/theweek/daily0.8 https://rxinsider.ai/tech/daily0.8 https://rxinsider.ai/about/monthly0.4 https://rxinsider.ai/editorial-policy/monthly0.4 https://rxinsider.ai/sources/monthly0.4 https://rxinsider.ai/disclaimer/monthly0.4 https://rxinsider.ai/privacy/monthly0.4 https://rxinsider.ai/terms/monthly0.4 https://rxinsider.ai/contact/monthly0.4 https://rxinsider.ai/articles/currax-s-nocdurna-fda-nod-400m-branded-disruptor-upends-sleep-disorder-market-pl/2026-04-11monthly0.7 https://rxinsider.ai/articles/roche-s-lung-cancer-trial-upsets-the-oncology-table-market-dynamics-and-competit/2026-04-11monthly0.7 https://rxinsider.ai/articles/specialty-spend-surge-how-2026-hepatitis-c-therapy-innovations-are-redistributin/2026-04-11monthly0.7 https://rxinsider.ai/articles/cvs-health-s-tighter-grip-biologics-prior-authorization-denials-surge-to-42-in-2/2026-04-11monthly0.7 https://rxinsider.ai/articles/merck-s-new-r-d-vp-bets-big-on-mrna-what-s-really-shifting-after-covid/2026-04-11monthly0.7 https://rxinsider.ai/articles/j-j-bets-500m-on-ai-drug-discovery-and-a-new-cmo-to-oversee-the-gamble/2026-04-11monthly0.7 https://rxinsider.ai/articles/keytruda-s-25b-question-merck-s-playbook-as-patent-expiry-nears/2026-04-11monthly0.7 https://rxinsider.ai/articles/rinvoq-s-3-6b-surge-can-abbvie-hold-the-line-as-biosimilar-ra-pressures-build/2026-04-11monthly0.7 https://rxinsider.ai/articles/biosimilars-beyond-humira-new-pressures-and-unwritten-rules-for-stelara-keytruda/2026-04-11monthly0.7 https://rxinsider.ai/articles/mrna-vaccine-platforms-in-2025-chasing-infectious-disease-dollars-beyond-covid/2026-04-11monthly0.7 https://rxinsider.ai/articles/fda-accelerated-approval-crackdown-shifts-the-landscape-for-aduhelm-and-alzheime/2026-04-11monthly0.7 https://rxinsider.ai/articles/ftc-s-latest-actions-against-pbms-the-future-of-pharmaceutical-distribution-and-/2026-04-11monthly0.7 https://rxinsider.ai/articles/amazon-pharmacy-s-disruption-2025-pbm-contracting-challenges-and-prescription-fu/2026-04-11monthly0.7 https://rxinsider.ai/articles/the-2026-squeeze-biogen-s-alzheimer-s-launch-340b-margins-and-hospital-negotiati/2026-04-11monthly0.7 https://rxinsider.ai/articles/sanofi-s-1-8b-insomnia-bet-what-the-idorsia-deal-says-about-sleep-drugs-and-biop/2026-04-11monthly0.7 https://rxinsider.ai/articles/merck-bets-1-6-billion-upfront-on-quantal-ai-and-the-future-cost-curve-of-early-/2026-04-11monthly0.7 https://rxinsider.ai/articles/ai-discovered-antibiotics-hit-the-clinic-hype-resistance-and-the-harsh-economics/2026-04-11monthly0.7 https://rxinsider.ai/articles/how-pfizer-s-oncology-pipeline-drives-2025-specialty-pharmacy-network-negotiatio/2026-04-11monthly0.7 https://rxinsider.ai/articles/2026-biosecure-act-how-tougher-biosafety-rules-are-forcing-biotech-investors-to-/2026-04-11monthly0.7 https://rxinsider.ai/articles/novo-nordisk-cfo-departure-signals-financial-reset-after-40b-market-cap-surge-on/2026-04-11monthly0.7 https://rxinsider.ai/articles/pfizer-s-2026-biosimilar-bets-revenue-shifts-after-enbrel-and-humira-patent-clif/2026-04-11monthly0.7 https://rxinsider.ai/articles/regeneron-and-alnylam-s-800m-bet-the-real-economics-behind-cardiovascular-rnai-s/2026-04-11monthly0.7 https://rxinsider.ai/articles/after-xeljanz-how-pfizer-plans-to-fill-a-2b-hole-post-2025-patent-cliff/2026-04-11monthly0.7 https://rxinsider.ai/articles/roche-s-2-1-billion-avacta-deal-betting-big-on-drug-delivery-and-oncology-engine/2026-04-11monthly0.7 https://rxinsider.ai/articles/eli-lilly-s-2-4-billion-dice-therapeutics-bet-pipeline-risk-platform-ambition-an/2026-04-09monthly0.7 https://rxinsider.ai/articles/gsk-names-first-chief-diversity-officer-amidst-regulatory-challenges-and-product/2026-04-09monthly0.7 https://rxinsider.ai/articles/novartis-spins-off-sandoz-what-the-10b-pure-play-means-for-biosimilar-strategies/2026-04-07monthly0.7 https://rxinsider.ai/articles/spinraza-s-2025-cliff-biogen-patent-expiry-and-the-new-pricing-squeeze/2026-04-04monthly0.7 https://rxinsider.ai/articles/why-aetna-s-2026-formulary-drop-hits-eliquis-and-what-it-means-for-anticoagulant/2026-04-02monthly0.7 https://rxinsider.ai/articles/crispr-in-the-real-world-vertex-and-crispr-therapeutics-shake-up-rare-disease-ec/2026-03-28monthly0.7 https://rxinsider.ai/articles/aetna-s-2026-step-therapy-expansion-biologic-manufacturers-face-7b-battleground/2026-03-26monthly0.7 https://rxinsider.ai/articles/crispr-therapeutics-cs37-in-hemophilia-b-breakthrough-candidate-or-regulatory-ga/2026-03-24monthly0.7 https://rxinsider.ai/articles/state-pbm-legislation-2025-2026-national-chains-absorb-independents-scramble/2026-03-21monthly0.7 https://rxinsider.ai/articles/the-week-in-pharma-lilly-bets-2-5b-on-alzheimer-s-pfizer-shifts-oncology-gears-p/2026-03-14monthly0.7 https://rxinsider.ai/articles/biosimilar-adoption-rates-abp-959-s-market-share-challenge-to-soliris-after-2025/2026-03-12monthly0.7 https://rxinsider.ai/articles/astrazeneca-names-new-cfo-as-16b-in-annual-revenue-nears-patent-cliff-what-happe/2026-03-10monthly0.7 https://rxinsider.ai/articles/lilly-s-mounjaro-pricing-strategy-gross-to-net-math-behind-market-dominance/2026-03-06monthly0.7 https://rxinsider.ai/articles/patient-access-and-insurer-costs-the-ongoing-battle-over-copay-accumulator-progr/2026-03-03monthly0.7 https://rxinsider.ai/articles/amgen-s-27-8b-horizon-buy-betting-big-on-rare-diseases-revenue-multiples-and-pip/2026-02-27monthly0.7 https://rxinsider.ai/articles/nadac-price-trends-the-drug-categories-moving-most-this-quarter/2026-02-24monthly0.7 https://rxinsider.ai/articles/weekly-pharma-roundup-merck-s-11b-bet-fda-pushback-and-earnings-surprises/2026-02-21monthly0.7 https://rxinsider.ai/articles/late-stage-obesity-drugs-beyond-glp-1s-orforglipron-survodutide-and-the-oral-alt/2026-02-18monthly0.7 https://rxinsider.ai/articles/gross-to-net-dynamics-in-pharma-earnings-decoding-the-real-revenue-numbers/2026-02-13monthly0.7 https://rxinsider.ai/articles/the-revolving-door-between-pbms-and-regulators-career-paths-that-shape-drug-pric/2026-02-10monthly0.7 https://rxinsider.ai/articles/ira-price-negotiation-year-one-what-the-numbers-reveal-about-cms-drugmakers-and-/2026-02-05monthly0.7 https://rxinsider.ai/articles/how-pbm-rebate-negotiations-actually-work-the-formulary-placement-auction-that-s/2026-01-30monthly0.7 https://rxinsider.ai/articles/obesity-pipeline-beyond-glp-1s-orforglipron-survodutide-and-the-oral-disruptors/2026-01-27monthly0.7 https://rxinsider.ai/articles/ira-price-negotiation-year-one-who-blinked-who-balked-and-what-s-next-for-big-ti/2026-01-22monthly0.7 https://rxinsider.ai/articles/the-economics-of-pharma-mega-mergers-why-most-buyers-overpay/2026-01-19monthly0.7